Clinical trials
Cardiomyopathies clinical trials
Below are recruiting cardiomyopathies clinical trials, each written for real people, not researchers. We’re tracking 320 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06368518Recruiting
Study of hypertrophic cardiomyopathy in Austria
This study tracks people with hypertrophic cardiomyopathy, a heart muscle disease, to learn more about the condition and improve care. It does not test a new treatment but collects health information over time.
Linz, LinzAges 18 years+ - NCT06381778Recruiting
Taiwan registry study on hypertrophic cardiomyopathy
This study creates a registry (a detailed record) for people with hypertrophic cardiomyopathy, a condition where the heart muscle is thicker than normal. It aims to learn more about the condition over time.
New Taipei CityAges 20 years+ - NCT06431919Recruiting
Adding statin to carvedilol for cirrhosis with heart problems
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
ChandigarhAges 18–65 - NCT06464588RecruitingPhase 1
Testing safety of newborn stem cells for dilated cardiomyopathy in young adults and children
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
Atlanta, GeorgiaAges 4–40 - NCT06490250Recruiting
Breathing vs. movement exercises for hypertrophic cardiomyopathy
This study compares two types of gentle exercises—breathing muscle training and a traditional Chinese movement practice called Baduanjin—to see which helps people with hypertrophic cardiomyopathy feel better and improve their daily life. If you have a thickened heart muscle but are stable and have mild symptoms, you may be able to join.
IstanbulAges 18 years+ - NCT06570902Recruiting
Heart monitor vest after first bypass surgery
This study tests a wearable heart monitor vest (WCD) for people who have had their first coronary bypass surgery and have a weakened heart pump (ejection fraction below 35%). The vest watches for dangerous heart rhythms and can shock the heart back to normal if needed.
Bad Nauheim, HesseAges 18 years+ - NCT06580717RecruitingPhase 4
Testing empagliflozin for heart stiffness in hypertrophic cardiomyopathy
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
SeoulAges 19–80 - NCT06591260Recruiting
Heart biopsy and treatment for kids with heart inflammation
This study looks at using heart biopsies to find the cause of heart inflammation (myocarditis) in children and then tailoring treatment to that cause. It aims to improve care for children with or without irregular heartbeats.
Milan, MilanoAges birth–17 years - NCT06634108RecruitingPhase 1/Phase 2
Genistein for heart failure from ATTR amyloid cardiomyopathy
This trial tests whether genistein, a plant-based supplement, can help people with a specific type of heart disease called ATTR amyloid cardiomyopathy. You might join if you have heart failure with reduced pumping function and this rare protein condition.
London, OntarioAges 40–80 - NCT06661876Recruiting
Heart radiation therapy for heart failure
This trial tests if a low dose of radiation to the heart can help people with advanced heart failure feel better and improve heart function. It is for patients whose heart failure is stable but severe, and who are already on the best medications.
LeuvenAges 18 years+ - NCT06688396Recruiting
Finding early signs of dilated cardiomyopathy with AI and mobile screening
This trial uses a smartphone app to screen first-degree relatives of people with dilated cardiomyopathy (DCM) for early signs of the condition. It aims to detect heart muscle weakness before symptoms start, so that treatment can begin sooner.
Lancaster, PennsylvaniaAges 18 years+ - NCT06741995Recruiting
Testing antibodies to predict heart muscle disease progression
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
Wuhan, HubeiAges 18–75 - NCT06793020Recruiting
Study of sepsis-related heart damage using a math model
This trial tests a new mathematical model to better diagnose and treat heart problems caused by sepsis. It includes adults with sepsis or septic shock who need strong blood pressure support.
VilniusAges 18 years+ - NCT06836011Recruiting
Heart valve leakage study in a type of amyloid heart disease
This study looks at how common and how serious heart valve leaks are in people with transthyretin amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart). The goal is to better understand these leaks and how they affect long-term health.
Graz, StyriaAges 18 years+ - NCT06846086RecruitingPhase 3
Melatonin for heart muscle protection
This trial tests if adding melatonin to standard heart medication helps protect the heart muscle in people with cardiomyopathy. If you are stable on your current heart meds, you may be able to join.
Dakahlia, Egypt, MansouraAges 18 years+ - NCT06920030Recruiting
Testing a new heart device for heart failure
This trial tests a new device that delivers a gentle electrical current to the heart to improve its pumping strength. It is for people with a certain type of heart failure caused by weak heart muscle, not a blocked artery.
Banja Luka, Republic of SrbskaAges 18–75 - NCT06922851Recruiting
Protein filter therapy for dilated cardiomyopathy
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
Wuhan, HubeiAges 18–75 - NCT06922994RecruitingPhase 2
Testing atorvastatin for arrhythmogenic cardiomyopathy
This trial tests if a common cholesterol medicine, atorvastatin, can slow the progression of arrhythmogenic cardiomyopathy, a genetic heart condition that can cause abnormal heart rhythms. If you have this condition, joining this study may help researchers find a new way to protect your heart.
Pavia, PVAges 18 years+ - NCT06935253Recruiting
AI to Improve Cardiology Care
This trial tests whether large language models (a type of AI that understands human language) can help cardiologists give better care. If you are a qualified cardiologist who currently treats patients, you may be eligible.
Palo Alto, CaliforniaAges 18 years+ - NCT06948344Recruiting
Genetics study for inherited heart muscle disease
This study is looking for people with inherited heart muscle disease that may be genetic. It uses advanced genetic testing to better understand the cause.
SeoulAges 19 years+ - NCT07006493Recruiting
Radiofrequency ablation for obstructive hypertrophic cardiomyopathy
This trial tests a new treatment that uses radiofrequency energy (similar to heat) to shrink the thickened heart muscle blocking blood flow. It is for people with obstructive hypertrophic cardiomyopathy who have symptoms despite medication and are not able or willing to have heart surgery.
Beijing, Beijing MunicipalityAges 18–80 - NCT07021963RecruitingPhase 2
Long-term safety study of HRS-1893 for hypertrophic cardiomyopathy
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
Beijing, Beijing MunicipalityAges 18–85 - NCT07021976RecruitingPhase 3
A study of HRS-1893 for obstructive hypertrophic cardiomyopathy
This trial tests an investigational drug called HRS-1893 in people with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. The study aims to see if the drug can improve symptoms and heart function.
Beijing, Beijing MunicipalityAges 18–85 - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
La Jolla, CaliforniaAges 18 years+
Hear when a new Cardiomyopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiomyopathies?
- Yes. Clin2 currently lists 320 recruiting cardiomyopathies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiomyopathies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.